<DOC>
	<DOCNO>NCT01932099</DOCNO>
	<brief_summary>A study ass safety effectiveness Direct Flow Medical aortic valve system . This people severe aortic stenosis well enough undergo surgical repair . The delivery device do via femoral artery .</brief_summary>
	<brief_title>TranScatheter Aortic Valve RepLacement System US Feasibility Trial</brief_title>
	<detailed_description>The Direct Flow Medical Transcatheter Aortic Valve System indicate symptomatic patient require replacement native aortic valve predict operative mortality serious morbidity risk equal great 50 % 30 day surgical aortic valve replacement deem unsuitable surgery .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . The patient severe senile degenerative aortic valve stenosis determine rest dobutamine stress echocardiogram Doppler , simultaneous pressure recording cardiac catheterization define : mean gradient &gt; 40 mmHg peak jet velocity &gt; 4.0 m/s aortic valve area ≤0.8 cm2 aortic valve area index ≤0.5 cm2/m2 . 2 . The patient moderate severe symptom aortic valve stenosis ( NYHA Functional Class ≥III ) . 3 . The patient must predict risk operative mortality serious irreversible morbidity &gt; 50 % 30 day , deem suitable surgery reason . This conclusion shall base consensus one cardiologist two cardiac surgeon investigational site careful consideration patient 's STS risk score comorbidities , least one surgeon participate decision personally examine patient . 4 . The patient inform nature study , agree provision , willing comply protocolspecified followup evaluation provide write informed consent , approve appropriate IRB . Exclusion Criteria 1 . Left ventricular ejection fraction ( LVEF ) &lt; 20 % determine rest echocardiogram 2 . Patients acute MI within 30 day precede index procedure . 3 . Any percutaneous coronary peripheral interventional procedure perform within 30 day prior study procedure 4 . Patients impaired renal function ( estimate Glomerular Filtration Rate [ eGFR ] &lt; 20cc/min , calculate serum creatinine CockcroftGault formula ) 5 . Patients platelet count &lt; 50,000 cells/mm³ WBC &lt; 1000 cells/mm³ within 7 day prior index procedure . 6 . Patients history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate , refuse transfusion . 7 . Patients receive organ transplant wait list organ transplant . 8 . Patients know medical illness ( e.g . carcinoma , chronic liver disease , chronic renal disease chronic end stage pulmonary disease ) know history substance abuse may cause noncompliance protocol , confound data interpretation associate life expectancy le one year , expectation patient improve despite treatment aortic stenosis . 9 . Patients know hypersensitivity contraindication aspirin , heparin , clopidogrel/ticlopidine , and/or contrast sensitivity adequately premedicated . 10 . Patients history stroke transient ischemic attack ( TIA ) within prior 6 month . 11 . Patients active gastrointestinal ( GI ) bleeding within prior 6 month . 12 . Patients present hemodynamic instability cardiogenic shock define low cardiac output , vasopressor dependence , mechanical hemodynamic support . 13 . Patients plan treatment investigational device procedure study period , currently participate investigational drug another device trial 14 . Any planned surgical , percutaneous coronary peripheral procedure perform prior 30 day followup TAVR procedure . 15 . Untreated clinically significant coronary artery disease require revascularization 16 . Transesophageal echocardiography ( TEE ) contraindicate 17 . Active endocarditis sepsis within 6 month prior study procedure 18 . Dementia ( result either inability provide inform consent trial/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) 19 . Congenital bicuspid unicuspid valve determine echocardiography 20 . Prior aortic mitral valve surgery preexist prosthetic heart valve position 21 . Native valve annulus diameter &lt; 19mm &gt; 26mm determine screen CT scan 22 . Extreme asymmetrical calcification native aortic valve determine screen CT scan 23 . Echocardiographic evidence intracardiac mass , thrombus , vegetation , spontaneous echo contrast leave atrium 24 . &gt; 3+ aortic regurgitation , mitral regurgitation tricuspid regurgitation 25 . Moderate severe mitral stenosis 26 . Thoracic aortic aneurysm ( TAA ) abdominal aortic aneurysm ( AAA ) &gt; 5.0 cm 27 . Presence endovascular stent graft treatment AAA TAA 28 Hypertrophic obstructive cardiomyopathy 29 . Patients severe peripheral arterial disease precludes sheath vascular access ( e.g . luminal diameter le 6.5 mm , severe obstructive calcification severe tortuosity )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pathological constriction ; restrict outflow , stenosis</keyword>
</DOC>